Surgical treatments for lentigo maligna: A review

Dermatologic Surgery

Volumn 37, Issue 9, 2011, Pages 1210-1228

  McLeod, Michael ^a   Choudhary, Sonal ^a   Giannakakis, Georgios ^b   Nouri, Keyvan ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Private Practice   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

ACTINIC KERATOSIS; BASAL CELL CARCINOMA; CHEMOSIS; CLINICAL FEATURE; CONDYLOMA ACUMINATUM; CONJUNCTIVITIS; CRYOSURGERY; CRYOTHERAPY; CURETTAGE; ELECTROSURGERY; ERYTHEMA; HUMAN; IMMUNOHISTOCHEMISTRY; INFLUENZA; KERATITIS; LASER SURGERY; MALIGNANT LENTIGO; MEDLINE; PRIORITY JOURNAL; PRURITUS; RADIOTHERAPY; RECURRENCE RISK; REVIEW; VISUAL DISORDER;

AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CRYOSURGERY; CURETTAGE; ELECTROSURGERY; HUMANS; HUTCHINSON'S MELANOTIC FRECKLE; IMMUNOHISTOCHEMISTRY; LASER THERAPY; MOHS SURGERY; SKIN NEOPLASMS;

EID: 80052323294     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2011.02042.x     Document Type: Review

References (148)

1. Hutchinson J., Notes on the cancerous process and on new growths in general. Arch Surg (London) 1890; 2: 83-6.
2. Cohen LM., Lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol 1995; 33: 923-36.
3. Hutchinson J., On tissue dotage. Arch Surg (London) 1892; 3: 315-22.
4. Hutchinson J., On cancer. Arch Surg (London) 1893; 4: 61-3.
5. Hutchinson J., Lentigo-melanosis: a further report. Arch Surg (London) 1894; 5: 254-6.
6. Hutchinson J., President's address at the Third International Congress of Dermatology. Arch Surg (London) 1896; 7: 297-317.
7. Dubreuilh MW., Lentigo malin des viellards. Ann Dermatol Syphil (Paris) 1894; 5: 1092-9.
8. Dubreuilh MW., De la mélanose circonscrite précancé reuse. Ann Dermatol Syphil 1912; 3: 129-51, 205-30.
9. Dubow BE, Ackeman AB., Malignant melanoma in situ: the evolution of a concept. Mod Pathol 1990; 3: 734-44.
10. Finan MC, Perry HO., Lentigo maligna: a form of melanoma in situ. Geriatrics 1982; 37: 113-5.
11. Silvers DN., Focus on melanoma: the therapeutic dilemma of lentigo maligna (Hutchinson's freckle). J Dermatol Surg Oncol 1976; 2: 301-3.
12. Flotte TJ, Mihm MCJ., Lentigo maligna and malignant melanoma in situ, lentigo maligna type. Hum Pathol 1999; 30: 533-6. (Pubitemid 29218046)
13. Tannous ZS, Lerner LH, Duncan LM, Mihm MC Jr., et al,. Progression to invasive melanoma from malignant melanoma in situ, lentigo maligna type. Hum Pathol 2000; 31: 705-8. (Pubitemid 30445474)
14. Michalopoulos P, Yawalkar N, Brönnimann M, Kappeler A, et al,. Characterization of the cellular infilitrate during successful topical treatment of lentigo maligna with imiquimod. Br J Dermatol 2004; 151: 903-6. (Pubitemid 39482129)
15. Wayte DM, Helwig EB., Melanotic freckle of Hutchinson. Cancer 1968; 21: 893.
16. Agarwal-Antral N, Bowen GM, Gerwels JW., Histologic evaluation of lentigo maligna with permanent sections: implications regarding current guidelines. J Am Acad Dermatol 2002; 47: 743-8. (Pubitemid 35239337)
17. Megahead M, Schon M, Selimovic D., Reliability of diagnosis of melanoma in situ. Lancet 2002; 359: 1921-2. (Pubitemid 34615774)
18. McKenna JK, Florell SR, Goldman GD, Bowen GM,. Lentigo maligna/lentigomaligna melanoma: current state of diagnosis and treatment. Dermatol Surg 2006; 32: 493-504.
19. Wolff K, Johnson RA., Melanoma precursors and primary cutaneous melanoma. In: Wolff K, Johnson RA, editors. Fitzpatrick's Color Atlas and Synopsis of Clinical Dermatology. 6th Ed. New York: McGraw-Hill; 2009.
20. Clark WJ, Mihm MJ., Lentigo maligna and lentigo-maligna melanoma. Am J Pathol 1969; 55.
21. Davis J, Pack GT, Higgins GK., Melanotic freckle of Hutchinson. Am J Surg 1967; 113: 457-63.
22. Weinstock MA, Sober AJ., The risk of progression of lentigo maligna to lentigo maligna melanoma. Br J Dermatol 1987; 116: 303-10. (Pubitemid 17030533)
23. Hunter J, Zaynoun S, Paterson W, Bleehen SS, et al,. Cellular fine structure in the invasive nodules of different histogenetic types of malignant melanoma. Br J Dermatol 1978; 98: 255-72. (Pubitemid 8287311)
24. Raziano RM, Clark GS, Cherpelis BS, Sondak VK, et al,. Staged margin control techniques for sugical excision of lentigo maligna. G Ital Venereol 2009; 144: 259-70.
25. Bub JL, Berg D, Slee A, Odland PB,. Management of lentigo maligna and lentigo maligna melanoma with staged excision. Arch Dermatol 2004; 140: 552-8. (Pubitemid 38668962)
26. Möller GM, Pappas-Politis E, Zager JS, Santiago LA, et al,. Surgical management of melanoma-in-situ using a staged marginal and central excision technique. Ann Surg Oncol 2009; 16: 1526-36.
27. Osborne JE, Hutchinson PE., A follow-up study to investigate the efficacy of initial treatment of lentigo maligna with surgical excision. Br J Plast Surg 2002; 55: 611-5. (Pubitemid 35469781)
28. Pitman GH, Kopf AW, Bart RS, Casson PR,. Treatment of lentigo maligna and lentigo maligna melanoma. J Dermatol Surg Oncol 1979; 5: 727-37. (Pubitemid 10240696)
29. Coleman WP III, Davis RS, Reed RJ, Krementz ET,. Treatment of lentigo maligna and lentigo maligna melanoma. J Dermatol Surg Oncol 1980; 6: 476-9. (Pubitemid 10073530)
30. Tsang RW, Liu FF, Wells W, Payne DG,. Lentigo maligna of the head and neck. Results of treatment by radiotherapy. Arch Dermatol 1994; 130: 1008-12. (Pubitemid 24255033)
31. Bricca GM, Brodland DG, Zitelli JA., Immunostaining melanoma frozen sections: the 1 hr protocol. Dermatol Surg 2004; 30: 403-8. (Pubitemid 38524161)
32. Huilgol SC, Selva D, Chen C, Hill DC, et al,. Surgical margins for lentigo maligna and lentigo maligna melanoma: the technique of mapped serial excision. Arch Dermatol 2004; 140: 1087-92. (Pubitemid 39223116)
33. Zalla MJ, Lim KK, Dicaudo DJ, Gagnot MM,. Mohs micrographic excision of melanoma using immunostains. Dermatol Surg 2000; 26: 771-84. (Pubitemid 30620524)
34. Erickson C, Miller SJ., Treatment options in melanoma insitu: topical and radiation therapy, excision and mohs surgery. Int J Dermatol 2010; 49: 482-91.
35. Johnson TM, Headington JT, Baker SR, Lowe L,. Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoam: the "square" procedure. J Am Acad Dermatol 1997; 37: 758-64. (Pubitemid 27500321)
36. Clark GS, Pappas-Politis EC, Cherpelis BS, Messina JL, et al,. Surgical management of melanoma in situ on chronically sun-damaged skin. Cancer Control 2008; 15: 216-24.
37. Bub JL, Berg D, Slee A, Odland PB,. Management of lentigo maligna and lentigo maligna melanoma with staged excision: a 5 year follow-up. Arch Dermatol 2004; 150: 552-8. (Pubitemid 38668962)
38. Mahoney MH, Joseph M, Temple CL., The perimeter technique for lentigo maligna: an alternative to mohs micrographic surgery. J Surg Oncol 2005; 91: 120-5. (Pubitemid 41077053)
39. Anderson KW, Baker SR, Lowe L, Su L, et al,. Treatment of head and neck melanoma, lentigo maligna subtype: a practical surgical technique. Arch Facial Plast Surg 2001; 3: 202-6.
40. Bosbous MW, Dzwierzynski MW, Neuberg M., Staged excision of lentigo maligna and lentigo maligna melanoma: a 10-year experience. Plast Recontr Surg 2009; 124: 1947-55.
41. Dhawan SS, Wolf DJ, Rabinovitz HS, Poulos E,. The use of rush permanent sections in therapy. Arch Dermatol 1990; 126: 928-30. (Pubitemid 20224551)
42. Robinson JK., Margin control for lentigo maligna. J Am Acad Dermatol 1994; 31: 79-85. (Pubitemid 24198168)
43. Cohen LM, MCall MW, Zax RH,. Mohs micrograhic surgery for lentigo maligna and lentigo maligna melanoma. A follow-up study. Dermatol Surg 1998; 24: 673-7. (Pubitemid 28294414)
44. Stonecipher MR, Leshin B, Patrick J, White WL,. Management of lentigo maligna and lentigo maligna melanoma with paraffin-embedded tangential sections: utility of immunoperoxidase staining and supplemental vertical sections. J Am Acad Dermatol 1993; 29: 589-94. (Pubitemid 23289561)
45. Mohs FE., Chemosurgical treatment of melanoma: a microscopically controlled method of excision. Arch Derm Syphilol 1950; 62: 269-79.
46. Mohs FE., Chemosurgery for melanoma. Arch Dermatol 1977; 113: 285-91. (Pubitemid 8054405)
47. Mohs FE., Microscopically controlled surgery for periorbital melanoma: fixed-tissue and fresh-tissue techniques. J Dermatol Surg Oncol 1985; 11: 284-91. (Pubitemid 16182510)
48. Mohs FE., Micrographic surgery for satellites and in-transit metastases of malignant melanoma. J Dermatol Surg Oncol 1986; 12: 471-6. (Pubitemid 16077039)
49. Zitelli JA, Mohs FE, Larson P, Snow S,. Mohs micrographic surgery for melanoma. Dermatol Clin 1989; 7: 833-43. (Pubitemid 19244941)
50. Kaspar TA, Wagner RFJ., Mohs micrographic surgery for thin stage I malignant melanoma: rational for a modern management strategy. Cutis 1992; 50: 350-1.
51. Walling HW, Scupham RK, Bean AK, Ceilley RI,. Staged excision versus Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma. Dermatol Surg 2007; 57: 659-64. (Pubitemid 47393585)
52. Zitelli JA, Brown C, Hanusa BH., Mohs micrograhic surgery for the treatment of primary cutaneous melanoma. J Am Acad Dermatol 1997; 37: 236-45. (Pubitemid 27355710)
53. Prieto VG, Argenyi ZB, Barnhill RL, Duray PH, et al,. Are en face frozen sections accurate for diagnosing margin status in melanocytic lesions? Am J Clin Pathol 2003; 120: 203-8. (Pubitemid 37046354)
54. Barlow RJ, White CR, Swanson NA., Mohs micrographic surgery using frozen sections alone may be unsuitable for detecting single atypical melanocytes at the margins of melanoma in situ. Br J Dermatol 2002; 146: 290-4. (Pubitemid 34264402)
55. Cohen LM, McCall MW, Hodge SJ, Freedman JD, et al,. Successful treatment of lentigo maligna and lentigo maligna melanoma with mohs micrographic surgery aided by rush permanent sections. Cancer 1994; 73: 2964-70. (Pubitemid 24170769)
56. Lee MR, Ryman WJ., Treatment of lentigo maligna with total circumferential margin control using vertical and horizontal permanent sections: a retrospective study. Australas J Dermatol 2008; 49: 196-201.
57. Kelly LC, Starkus L., Immunohistochemical staining of lentigo maligna during mohs micrographic surgery using MART-1. J Am Acad Dermatol 2002; 46: 78-84. (Pubitemid 34073482)
58. Zitelli JA, Moy RL, Abell E., The reliability of frozen sections in the evaluation of surgical margins for melanoma. J Am Acad Dermatol 1991; 24: 102-6.
59. Stranahan D, Cherpelis BS, Glass LF, Ladd S, et al,. Immunohistochemical stains in Mohs surgery: a review. Dermatol Surg 2009; 35: 1023-34.
60. KaderElTal A, Abrou AE, Stiff MA, Mehregan DA,. Immunostaining in Mohs micrographic surgery: a review. Dermatol Surg 2010; 36: 275-90.
61. Gowen AM, Vogel AM, Hoak D, Gough F, et al,. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol 1986; 123: 195-203. (Pubitemid 16072518)
62. Wick MR, Swanson PE, Rocamora A., An Immunohistochemical study of 200 parafin-embedded cutaneous tumors. J Cutan Pathol 1988; 15: 201-7.
63. Bacchi CE, Bonetti F, Pea M, Martignoni G, et al,. HMB-45: a review. Appl Immunohistochem 1996; 4: 73-85. (Pubitemid 126481824)
64. Ordõñez NG, Xialong J, Hickey RC., Comparison of HMB-45 monoclonal antibody and S-100 protein in the immunohistochemical diagnosis of melanoma. Am J Clin Pathol 1988; 90: 385-90.
65. Fernando SS, Johnson S, Bate J., Immunohistochemical analysis of cutaneous malignant melanoma: comparison of S-100 protein, HMB-45 monoclonal antibody and NKI/C3 monoclonal antibody. Pathology 1994; 26: 16-9. (Pubitemid 24047196)
66. Duray PH, Palazzo J, Gown AM, Ohuchi N,. Melanoma cell heterogeneity. A study of two monoclonal antibodies compared with S-100 protein in paraffin sections. Cancer 1988; 61: 2460-8.
67. Skelton HG III, Smith KJ, Barrett TL, Lupton GP, et al,. HMB-45 staining in benign and malignant melanocytic lesions. A reflection of celllular activation. Am J Dermatopathol 1991; 13: 543-50.
68. Lampert A, Thomine E, Lauret P, Hemet J,. Comparative study of HMB-45 monoclonal antibody uptake on various benign and malignant melanocytic lesions [in French]. Ann Pathol 1993; 13: 100-7. (Pubitemid 23242071)
69. Ribé A, McNutt NS., S100A Protein expression in the distinction between lentigo maligna and pigmented actinic keratosis. Am J Dermatopathol 2003; 25: 93-9. (Pubitemid 36350453)
70. ELShawbrawi-Caelen L, Kerl H, Cerroni L., Melan-A: not a helpful marker in distinction between melanoma in situ on sun-damaged skin and pigmented actinic keratosis. Am J Dermatopathol 2004; 26: 364-6. (Pubitemid 39287355)
71. Albertini JG, Elston DM, Libow LF, Smith SB, et al,. Mohs micrographic surgery for melanoma: a case series, a comparative study of immunostains, an informative case report, and a unique mapping technique. Dermatol Surg 2002; 28: 656-65. (Pubitemid 34913271)
72. Stranahan DR, Cherpelis BS, Fenske NA, Glass LF,. Advances in immunostains used in Mohs Surgery. J Drugs Dermatol 2010; 9: 760-3.
73. Miettinen M, Fernandez M, Franssila K, Gatalica Z, et al,. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers. Am J Surg Pathol 2001; 25: 205-11. (Pubitemid 32167502)
74. Granter SR, Weilbaecher KN, Quigley C, Fisher DE,. Role for microphthalmia transcription factor in the diagnosis of metastatic malignant melanoma. Appl Immunohistochem Mol Morphol 2002; 10: 47-51. (Pubitemid 34178276)
75. King R, Googe PB, Weilbaecher KN, Mihm MC Jr,., et al. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors. Am J Surg Pathol 2001; 25: 51-7. (Pubitemid 32001832)
76. King R, Weilbaecher KN, McGill G, Cooley E, et al,. Microphthalmia transcription factor. A sensitive and specific melanocyte marker for MelanomaDiagnosis. Am J Pathol 1999; 155: 731-8. (Pubitemid 29426819)
77. Busam KJ, Iversen K, Coplan KC, Jungbluth AA,. Analysis of microphthalmia transcription factor expression in normal tissues and tumors, and comparison of its expression with S-100 protein, gp100, and tyrosinase in desmoplastic malignant melanoma. Am J Surg Pathol 2001; 25: 197-204. (Pubitemid 32167501)
78. Busam KJ, Kucukgöl D, Sato E, Frosina D, et al,. Immunohistochemical analysis of novel monoclonal antibody PNL2 and comparison with other melanocyte differentiation markers. Am J Surg Pathol 2005; 29: 400-6. (Pubitemid 40321977)
79. Kimyai-Asadi A, Ayala GB, Goldberg LH, Vujevich J, et al,. The 20 minute rapid MART-1 Immunostain for Malignant Melanoma Frozen Sections. Dermatol Surg 2008; 34: 498-500. (Pubitemid 351442694)
80. Cherpelis BS, Moore R, Ladd S, Chen R, et al,. Comparison of MART-1 Frozen Sections to Permanent Sections using a rapid 19-minute protocol. Dermatol Surg 2009; 35: 207-13.
81. Davis DA, Kurtz KA, Robinson RA., Ultrarapid staining for cutaneous melanoma: study and protocol. Dermatol Surg 2005; 31: 753-6. (Pubitemid 43110101)
82. Graham GF, George MN, Patel M., Cryosurgery. In:, Nouri K, Leal-Khouri S, editors. Techniques in Dermatologic Surgery. Edinburgh: Mosby; 2003. p. 183-4.
83. Gage AA, Meenaghan MA, Natiella JR, Greene GW Jr,. Sensitivity of pigmented mucosa and skin to freezing injury. Cryobiology 1979; 16: 348-61. (Pubitemid 10234259)
84. Kuflick EG, Gage AA., Cryosurgery for lentigo maligna. J Am Acad Dermatol 1994; 31: 75-8. (Pubitemid 24198167)
85. Dawber RPR, Wilkinson JD., Melanotic freckle of Hutchinson: treatment of macular and nodular phases with cryotherapy. Br J Dermatol 1979; 101: 47-9. (Pubitemid 10134315)
86. Zacarin SA., Cryosurgical treament of lentigo maligna. Arch Dermatol 1982; 118: 89-92.
87. Böhler-Sommeregger K, Schuller-Petrovic S, Neumann R, Müller E,. Cryosurgery of lentigo maligna. Plast Recontr Surg 1992; 90: 436-40; discussion 41-4.
88. Böhler-Sommeregger K, Schuller-Petrovic S, Knobler R, Neumann PR,. Reactive lentiginous hyperpigmentation after cryosurgery for lentigo maligna. J Am Acad Dermatol 1992; 27: 523-6.
89. Collins P, Rogers S, Goggin M, Manning W,. Cryotherapy for lentigo maligna. Clin Exp Dermatol 1991; 16: 433-5.
90. Gaspar ZS, Dawber RPR., Treatment of lentigo maligna. Australas J Dermatol 1997; 38: 1-8. (Pubitemid 27166513)
91. Powell AM, Robson AM, Russell-Jones R, Barlow RJ,. Imiquimod and lentigo maligna: a search for prognostic features in a clinicopahtological study with long-term follow-up. Br J Dermatol 2009; 160: 994-8.
92. Mahoney MH, Joseph MG, Temple C., Topical imiquimod therapy for lentigo maligna. Ann Plast Surg 2008; 61: 419-24.
93. Buettiker UV, Yawalkar NY, Braathen LR, Hunger RE,. Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients. Arch Dermatol 2008; 144: 943-5. (Pubitemid 352039751)
94. Chapman MS, Spencer SK, Brennick JB., Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream. Arch Dermatol 2003; 129: 943-4. (Pubitemid 36898941)
95. Ahmed I, Berth-Jones J., Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol 2000; 143: 843-5.
96. Borucki U, Metze D., Topical treatment of lentigo maligna melanoma with imiquimod 5% cream. Dermatology 2003; 207: 326-8. (Pubitemid 37329209)
97. deTroya-Martín T, Frieyro-Elicegui M, FúnezLiébana R, Aguilar Bernier M, et al,. Lentigo maligna managed with topical imiquimod and dermoscopy: report of two cases. Dermatol Surg 2008; 34: 1561-6.
98. Epstein E., Extensive lentigo maligna clearing with topical imiquimod. Arch Dermatol 2003; 139: 944-5. (Pubitemid 36898942)
99. Fleming CJ, Bryden AM, Evans A, Dawe RS, et al,. A pilot study of treatment of lentigo maligna with 5% imiquimod cream. Br J Dermatol 2004; 151: 485-8. (Pubitemid 39215164)
100. Hopson B, Richey D, Sajben FP., Treatment of lentigo maligna with imiquimod 5% cream. J Drugs Dermatol 2007; 6: 1037-40.
101. Kamin A, Eigentler TK, Radny P, Bauer J, et al,. Imiquimod in the treatment of extensive recurrent lentigo maligna. J Am Acad Dermatol 2005; 52: 51-2.
102. Kupfer-Bessaguet I, Guillet G, Misery L, Carre JL, et al,. Topical imiquimod treatment of lentigo maligna: clinical and histologic evaluation. J Am Acad Dermatol 2004; 51: 635-9. (Pubitemid 39278087)
103. Micali G, Lacarrubba F, Nardone B, Nasca MR,. Videodermatoscopy of lentigo maligna treated with imiquimod. J Drugs Dermatol 2008; 7: 1077-80.
104. Micantonio T, Fargnoli MC, Peris K., Usefulness of dermoscopy to monitor clinical efficacy of imiquimod treatment for lentigo maligna. Arch Dermatol 2006; 142: 530-1. (Pubitemid 43671665)
105. Naylor MF, Crowson N, Kuwahara R, Teague K, et al,. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol 2003; 149: 66-70.
106. Powell AM, Russell-Jones R., Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy. J Am Acad Dermatol 2004; 50: 792-6. (Pubitemid 38580565)
107. Ramsdell AM, Zeitouni N., Long-term follow-up of a hemifacial lentigo maligna treated using 5% imiquimod. Dermatol Surg 2009; 35: 287-90.
108. vanMeurs T, vanDoorn R, Kirtschig G., Recurrence of lentigo maligna after initial complete response to treatment with 5% imiquimod cream. Dermatol Surg 2007; 33: 623-6 discuss 26-7. (Pubitemid 46650379)
109. Wolf IH, Cerroni L, Kodama K, Kerl H,. Treatment of lentigo maligna (melanoma in situ) with immune response modifier imiquimod. Arch Dermatol 2005; 141: 510-4. (Pubitemid 40547412)
110. Cotter MA, McKenna JK, Bowen GM., Treatment of Lentigo Maligna with Imiquimod before Staged Excision. Dermatol Surg 2008; 34: 147-51.
111. Harrison LI, Skinner SL, Marbury TC, Owens ML, et al,. Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms. Arch Dermatol Res 2004; 296: 6-11. (Pubitemid 38828417)
112. Love WE, Bernhard JD, Bordeaux JS., Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol 2009; 145: 1431-8.
113. Murchison AP, Washington CV, Solomon AR, et al,. Ocular effects of immiquimod with treatment of eyelid melanoma in situ. Dermatol Surg 2007; 33: 1136-8. (Pubitemid 47339701)
114. Cannon PS, O'Donnell B, Huilgol SC, Selva D,. The ophthalmic side-effects of imiquimod therapy in the management of periocular skin lesions. Br J Ophthalmol 2010 Aug 10. [Epub ahead of print]. doi: DOI: 10.1136/bjo.2009. 178202.
115. Bowen G., Combination Therapy with Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna. Last accessed on April 28, 2010.
116. Wolf P., Imiquimod to detect residual lesions and prevent recurrence of Lentigo Maligna. Last accessed on April 28, 2010.
117. Arndt KA., Argon laser treatment of lentigo maligna. J Am Acad Dermatol 1984; 10: 953-7. (Pubitemid 14111147)
118. Kopera D., Treatment of lentigo maligna with the carbon dioxide laser. Arch Derm 1995; 131: 735-6.
119. Zalaudek I, Horn M, Richtig E., Local recurrence in melanoma in situ: influence of sex, age, site, of involvement and therapeutic modalities. Br J Dermatol 2003; 148: 703-8. (Pubitemid 36629748)
120. Iyer S, Goldman M., Treatment of lentigo maligna with combination laser therapy: recurrence at 8 months after initial resolution. J Cosmet Laser Ther 2003; 5: 49-52. (Pubitemid 36626783)
121. Madan V, August PJ., Lentigo maligna-outcomes of treament with Q-switched Nd: YAG and alexandrite lasers. Dermatol Surg 2009; 35: 607-11, discussion 11-2.
122. Lee PK, Rosenberg CN, Tsao H, Sober AJ,. Failure of Q-switched ruby laser to eradicate atypical-appearing solar lentigo: report of two cases. J Am Acad Dermatol 1998; 38 (2 Pt 2): 314-7. (Pubitemid 28115239)
123. Miescher G., Über Melanotische Präcancerose. Oncologia 1954; 7: 92-4.
124. Miescher G., Die Behandlung der Malignen Melanome der Haut mit Einschluß der Melanotischen Präcancerose. Strahlentherapie 1960; 46: 25-35.
125. Harwood AR, Cummings BJ., Radiotherapy for malignant melanoma: a reappraisal. Cancer Treat Rev 1981; 8: 271-82.
126. Panizzon RG., Radiotherapy of lentigo maligna and lentigo maligna melanoma. Skin Cancer 1999; 14: 203-7. (Pubitemid 30064745)
127. Schmid-Wendtner MH, Brunner B, Konz B, Kaudewitz P, et al,. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. J Am Acad Dermatol 2000; 43: 477-82. (Pubitemid 30666739)
128. Petratos MA, Kopf AW, Bart RS, Grisewood EN, et al,. Treatment of melanotic freckle with x-rays. Arch Derm 1972; 106: 189-94.
129. Kopf AW, Bart RS, Gladstein AH., Treatment of melanotic freckle with x-rays. Arch Dermatol 1976; 112: 801-7.
130. Farshad A, Burg G, Panizzon R, Dummer R,. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft x-rays. Br J Dermatol 2002; 146: 1042-46. (Pubitemid 34779486)
131. Dancuart F, Harwood AR, Fitzpatrick PJ., The radiotherapy of lentigo maligna and lentigo maligna melanoma of the head and neck. Cancer 1980; 45: 2279-83. (Pubitemid 10109115)
132. Harwood AR., Conventional radiotherapy in the treatment of lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol 1982; 6: 310-6. (Pubitemid 12183574)
133. Harwood AR., Conventional fractionated radiotherapy for 51 patients with lentigo maligna and lentigo maligna melanoma. Int J Radiat Oncol Biol Phys 1983; 9: 1019-21. (Pubitemid 13026517)
134. Christie DR, Tiver KW., Radiotherapy for melanotic freckles. Australas Radiol 1996; 40: 331-3. (Pubitemid 26285790)
135. Robinson JK., Current histologic preparation methods for mohs micrographic surgery. Dermatol Surg 2001; 27: 555-60. (Pubitemid 32552910)
136. Huang CC., Comments on "Lentigo Maligna-Outcomes of Treatment with Q-Switched Nd: YAG and alexandrite lasers. Dermatol Surg 2009; 35: 611-2.
137. Mamoon AM, Gamal-Eldeen AM, Ruppel ME, Smith RJ, et al,. In vitro efficiency and mechanistic role of indocyanine green as photodynamic therapy agent for human melanoma. Photodiagn Photodyn Ther 2009; 6: 105-16.
138. Hill DC, Gramp AA., Surgical treatment of lentigo maligna and lentigo maligna melanoma. Australas J Dermatol 1999; 40: 25-40.
139. Malhotra R, Chen C, Huilgol SC, Hill DC, et al,. Mapped serial excision for periocular lentigo maligna and lentigo maligna melanoma. Opthalmology 2003; 110: 2011-8. (Pubitemid 37163323)
140. Jejurikar SS, Borschel GH, Johnson TM, Lowe L, Johnson TM, et al,. Immediate, optimal reconstruction of facial lentigo maligna and melanoma following total peripheral margin control. Plast Recontr Surg 2007; 120: 1249-55. (Pubitemid 47493947)
141. Clayton BD, Leshin B, Hitchcock MG, Marks M, et al,. Utility of rush paraffin-embedded tangential sections in the management of cutaneous neoplasms. Dermatol Surg 2000; 26: 671-8. (Pubitemid 30470633)
142. Temple CL, Arlette JP., Mohs micrographic surgery in the treatment of lentigo maligna and melanoma. J Surg Oncol 2006; 94: 287-92. (Pubitemid 44330851)
143. Bhardwaj SS, Tope WD, Lee PK., Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma using Mel-5 immunostaining: University of Minnesota experience. Dermatol Surg 2006; 32: 690-6. (Pubitemid 43742533)
144. Bienert TN, Trotter MJ, Arlette JP., Treatment of cutaneous melanoma of the face by Mohs micrographic surgery. J Cutan Med Surg 2003; 7: 25-30. (Pubitemid 36350855)
145. Bene NI, Healy C, Coldiron BM., Mohs micrographic surgery is accurate 95.1% of the time for melanoma in situ: a prospective study of 167 cases. Dermatol Surg 2008; 34: 660-4. (Pubitemid 351569486)
146. Arndt KA., New pigmented macule appearing 4 years after argon laser treatment of lentigo maligna. J Am Acad Dermatol 1986; 14: 1092.
147. Orten SS, Waner M, Dinehart SM, Bardales RH, et al,. Q-switched neodymium: yttrium-aluminum-garnet laser treatment of lentigo maligna. Otolaryngol Head Neck Surg 1999; 120: 296-302. (Pubitemid 29135860)
148. Niiyama N, Niiyama S, Takasu H, Katsuoka K,. Progression of lentigo maligna into lentigo maligna melanoma following laser treatment. Eur J Dermatol 2007; 17: 252-3. (Pubitemid 46847799)